

Table S1 Subgroup analysis for the PFS and OS (month) when using different thoracic radiation doses

Variables	<45 Gy			≥45 Gy		
	Placebo	Anlotinib	P	Placebo	Anlotinib	P
PFS						
N	2	7		13	28	
Event	2	3		11	14	
Censored, n (%)	0 (0)	4 (57.14)		2 (15.38)	14 (50.00)	
Median	0.71	5.75		0.69	5.49	
95% CI	(0.66, 0.76)	(0.36, 5.75)	0.0462	(0.66, 0.82)	(2.79, 6.90)	<0.0001
OS						
N	2	7		13	28	
Event	1	2		8	8	
Censored, n (%)	1 (50.00)	5 (71.43)		5 (38.46)	20 (71.43)	
Median	6.67	7.29		4.37	10.51	
95% CI	(NE, NE)	(1.71, NE)	0.4795	(0.82, 7.82)	(6.97, NE)	0.0969

PFS, progression-free survival; OS, overall survival; CI, confidence interval.